Product Images Letrozole

This is a graph showing Kaplan-Meier estimates of time to progression for two medications, letrozole 2.5 mg and tamoxifen 20 mg. The graph is divided into months, but there is no further information or context provided.*

The text describes a figure, labeled as "Figure 4", which depicts Kaplan-Meier estimates of time to progression in a study involving megestrol acetate. The x-axis is labeled "TIME TO PROGRESSION (IN DAYS)" and the y-axis is not specified. The treatment groups are represented by lines with different markers, including Letrozole 0.5 mg and Letrozole 2.5 mg. The figure shows the progression over time, with the Letrozole 2.5 mg treatment having a slower progression rate than the Letrozole 0.5 mg treatment.*

The image shows a Kaplan-Meier plot with Time to Progression (in days) on the x-axis and treatment groups on the y-axis. The two treatment groups are Letrozole 0.5 mg and Letrozole 2.5 mg, and there is a third group labeled as "AG," which cannot be determined from the text. The plot shows the estimated probability of progression-free survival over time for each group.*

The text is a description of a medication called "Letrozole USP 2.5 mg" that comes in film-coated tablets. It is distributed by Aurobindo Pharma USA, Inc. and is made in India. The recommended storage temperature is between 20°C - 25°C (68°F - 77°F). The usual dosage information is available in the package insert. The text also mentions to keep the medication and all drugs out of the reach of children. The remaining text appears to be printing instructions and coding areas and is not relevant to the medication description.*